Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IvoLoC Trial
NCT07229417Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in Invasive Lobular Carcinoma (ILC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
Invasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on NCT07229417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229417.